Regulatory Approval (as Intangible Asset)
Definition
The authorisation granted by a government or regulatory body permitting a company to manufacture, market, or sell a product or service in a specific jurisdiction. Regulatory approvals — including drug approvals (FDA, EMA), financial service licences (FCA, MAS), telecommunications licences, and environmental permits — are recognised as contract-based intangible assets in purchase price allocations under IFRS 3 and ASC 805 when they arise from contractual or legal rights. Their value depends on barriers to obtaining equivalent approvals, remaining duration, and the protected revenue stream.
Complementary Terms
Concepts that frequently appear alongside Regulatory Approval (as Intangible Asset) in practice.
The regulatory process by which a pharmaceutical product receives authorisation for commercial sale, granted by agencies such as the FDA (US), EMA (EU), and MHRA (UK). Drug approval requires demonstration of safety, efficacy, and manufacturing quality through preclinical studies and clinical trials.
An intangible asset that meets the identifiability criteria under IFRS 3 or IAS 38, meaning it is either separable from the entity (can be sold, transferred, or licensed independently) or arises from contractual or legal rights. Identified intangible assets are recognised separately from goodwill in purchase price allocations.
An intangible asset for which there is no foreseeable limit to the period over which it is expected to generate net cash inflows for the entity. Under IAS 38 and ASC 350, indefinite-lived intangible assets are not amortised but must be tested for impairment at least annually and whenever there is an indication of impairment.
Intangible assets that are identified and recorded on the balance sheet for the first time as part of a business combination, despite having been unrecognised on the acquired company's own books. These assets — such as customer relationships, order backlogs, and proprietary technology — often represent a substantial portion of the total purchase price.
An identifiable intangible asset representing the value of unfulfilled orders or contracts at the date of a business combination. Backlog intangibles are recognised separately under purchase price allocation and are amortised as the underlying orders are fulfilled.
A non-physical asset that derives value from intellectual or legal rights, or from the competitive advantage it provides. Examples include brands, patents, software, customer relationships, data, organisational know-how, and human capital.
The proportion of a company's total assets or total investment that is attributable to intangible assets. A high intangible asset intensity — common in technology, pharmaceutical, and professional services firms — indicates that value creation is driven primarily by knowledge, data, and relationships rather than physical capital.
The economic return generated by a company's intangible asset base, expressed as income attributable to intangible assets divided by their estimated value. Yield on intangible assets provides a measure of how effectively a firm is monetising its intellectual property, brand, customer relationships, and other non-physical resources.
Put this knowledge to work
Use Opagio's free tools to measure and grow the intangible assets that drive your business value.